Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 1, 2012, Pages 88-94

  Holmes, Jordan A ^a   Wang, Andrew Z ^a,b   Hoffman, Karen E ^c   Hendrix, Laura H ^a   Rosenman, Julian G ^a,b   Carpenter, William R ^b,d   Godley, Paul A ^a,b   Chen, Ronald C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d University of North Carolina at Chapel Hill   (United States)

Author keywords

Decision making; Prostate cancer; Prostatectomy; Radiotherapy; Therapeutics

Indexed keywords

COMPLETE INFORMATION; CONSERVATIVE MANAGEMENT; DECISION MAKING PROCESS; GLEASON SCORES; LOGISTIC REGRESSIONS; MULTIVARIABLE ANALYSIS; NODE-NEGATIVE; PATTERNS OF CARE; PRIMARY TREATMENT; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PROSTATECTOMY; RADIATION ONCOLOGISTS; THERAPEUTICS;

DIAGNOSIS; LOGISTICS; PATIENT MONITORING; RADIOTHERAPY; SURGERY; UROLOGY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CRYOTHERAPY; EDUCATIONAL STATUS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NOMOGRAM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DECISION MAKING; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NOMOGRAMS; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; WATCHFUL WAITING;

EID: 84865691229     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.076     Document Type: Article

References (41)

1. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: Prostate cancer 2010 NCCN Fort Washington, PA
2. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
3. R.C. Chen, J.A. Clark, and J.A. Talcott Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function J Clin Oncol 27 2009 3916 3922
4. Y. Pardo, F. Guedea, and F. Aguiló Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment J Clin Oncol 28 2010 4687 4696
5. S.B. Clauser, P.A. Ganz, and J. Lipscomb Patient-reported outcomes assessment in cancer trials: Evaluating and enhancing the payoff to decision making J Clin Oncol 25 2007 5049 5050
6. M.S. Litwin, S. Greenfield, and E.P. Elkin Assessment of prognosis with the total illness burden index for prostate cancer: Aiding clinicians in treatment choice Cancer 109 2007 1777 1783
7. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
8. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial J Urol 181 2009 956 962
9. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
10. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
11. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
12. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
13. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial Lancet 373 2009 301 308
14. D.V. Makarov, B.J. Trock, and E.B. Humphreys Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005 Urology 69 2007 1095 1101
15. C. Zippin, D. Lum, and B.F. Hankey Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute Cancer 76 1995 2343 2350
16. M.K. Paasche-Orlow, R.M. Parker, and J.A. Gazmararian The prevalence of limited health literacy J Gen Intern Med 20 2005 175 184
17. G.K. Singh, B.A. Miller, and B.F. Hankey Area socioeconomic variations in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975-1999. NCI cancer surveillance monograph series, number 4 2003 National Cancer Institute Bethesda, MD
18. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106 2131
19. S.J. Freedland, A.W. Partin, and E.B. Humphreys Radical prostatectomy for clinical stage T3a disease Cancer 109 2007 1273 1278
20. S. Alkhateeb, S. Alibhai, and N. Fleshner Impact of positive surgical margins after radical prostatectomy differs by disease risk group J Urol 183 2010 145 150
21. J.I. Epstein, G. Pizov, and P.C. Walsh Correlation of pathologic findings with progression after radical retropubic prostatectomy Cancer 71 1993 3582 3593
22. J.L. Wright, B.L. Dalkin, and L.D. True Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality J Urol 183 2010 2213 2218
23. C.M. Moinpour, K.A. Hayden, and J.M. Unger Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy J Clin Oncol 26 2008 112 120
24. M. Ohori, M.W. Kattan, and C. Yu Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy Int J Urol 17 2010 534 540
25. N. Satake, M. Ohori, and C. Yu Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens Int J Urol 17 2010 267 272
26. K.C. Zorn, U. Capitanio, and C. Jeldres Multi-institutional external validation of seminal vesicle invasion nomograms: Head-to-head comparison of Gallina nomogram versus 2007 Partin tables Int J Radiat Oncol Biol Phys 73 2009 1461 1467
27. E.I. Heath, M.W. Kattan, and I.J. Powell The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer Urology 71 2008 151 155
28. D.M. Fanning, Y. Fan, and J.M. Fitzpatrick External validation of the 2007 and 2001 Partin tables in Irish prostate cancer patients Urol Int 84 2010 174 179
29. R. Ayyathurai, K. Ananthakrishnan, and R. Rajasundaram Predictive ability of Partin tables 2001 in a Welsh population Urol Int 76 2006 217 222
30. S.Y. Eskicorapci, E. Karabulut, and L. Turkeri Validation of 2001 Partin tables in Turkey: A multicenter study Eur Urol 47 2005 185 189
31. S. Naito, K. Kuroiwa, and N. Kinukawa Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: Data from the Clinicopathological Research Group for Localized Prostate Cancer J Urol 180 2008 904 909 discussion 909-910
32. M.L. Blute, E.J. Bergstralh, and A.W. Partin Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer J Urol 164 2000 1591 1595
33. J.B. Yu, D.V. Makarov, and R. Sharma Validation of the partin nomogram for prostate cancer in a national sample J Urol 183 2010 105 111
34. W. Underwood, S. De Monner, and P. Ubel Racial/ethnic disparities in the treatment of localized/regional prostate cancer J Urol 171 2004 1504 1507
35. E. Rapiti, G. Fioretta, and R. Schaffar Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis Cancer 115 2009 5556 5565
36. T.L. Jang, J.E. Bekelman, and Y. Liu Physician visits prior to treatment for clinically localized prostate cancer Arch Intern Med 170 2010 440 450
37. D.V. Makarov, J.B. Yu, and R.A. Desai The association between diffusion of the surgical robot and radical prostatectomy rates Med Care 49 2011 333 339
38. K.E. Hoffman, P.L. Nguyen, and M.H. Chen Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials J Urol 185 2011 116 120
39. S.K. Bechis, P.R. Carroll, and M.R. Cooperberg Impact of age at diagnosis on prostate cancer treatment and survival J Clin Oncol 29 2011 235 241
40. G.S. Cooper, B. Virnig, and C.N. Klabunde Use of SEER-Medicare data for measuring cancer surgery Med Care 40 2002 IV-43 IV-48
41. B.A. Virnig, J.L. Warren, and G.S. Cooper Studying radiation therapy using SEER-Medicare-linked data Med Care 40 2002 IV-49 IV-54